Dishman Carbogen shares rise by 9 pc after I-T department conducts search at offices
Ahmedabad: The share price of Dishman Carbogen Amcis rose by over 9 per cent on Thursday after officials of the Income Tax Department conducted search at the company's offices and manufacturing sites here.
The Swiss company provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries.
In a communication to stock exchanges, Dishman Carbogen said officials of the Income Tax Department conducted search at the company's offices and manufacturing sites from December 19 to 25.
"The company extended full cooperation to officials during the search and provided all the information sought. We at Dishman Carbogen Amcis Ltd follow the highest standards of corporate governance and financial discipline," it said.
"Our systems and processes are benchmarked by competent auditing and accounting standards, our dealings with our partners, investors, financial institutions and our clients are transparent and of the highest industry standards," it added.
Read Also: Cipla shares jump 2 pc post agreement with CitiHealth Imports
Dishman Carbogen's capabilities span from contract chemical process research and development to the supply of active pharmaceutical ingredients as well as drug products for pre-clinical studies, clinical trials and commercial use.
Read Also: Unichem Lab shares jump over 7 pc after USFDA nod for Atenolol tablets
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd